Shockwave Medical, Inc. SWAV recently announced the full U.S. commercial availability of the Shockwave L6 Peripheral Intravascular Lithotripsy (IVL) Catheter. This follows the receipt of the FDA’s ...
Physicians have a number of tools to treat coronary artery disease, the most common type of heart disease in the United States. But one breakthrough technology being offered at Catholic Medical Center ...
Shockwave Medical, Inc. SWAV, along with Genesis MedTech Group, received approval from China’s National Medical Products Administration for Intravascular Lithotripsy (“IVL”). The clearance paves the ...
Shockwave Medical specializes in developing and commercializing medical devices using IVL technology for treating calcified plaque in vascular and heart valve diseases. The company has achieved ...
Johnson & Johnson (J&J) MedTech’s Shockwave Medical has commenced the multicentre, prospective FORWARD CAD investigational device exemption (IDE) study of the Javelin coronary intravascular ...
ShockWave’s disruptive approach within the calcified cardiovascular disease space creates a first-mover advantage offering the opportunity of robust sales growth. ShockWave Medical’s business model ...
SANTA CLARA, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results